29 November - 2 December 2021

Exhibiting at Gene Therapy Analytical Development Summit

Next week we are again traveling through cyberspace and our target is the 3rd Annual Gene Therapy Analytical Development Summit. This is a conference dedicated to optimizing analytical methods to guarantee safe, high-quality, consistent, and efficacious gene therapy products.

We look forward to joining this virtual summit, the industry’s definitive and the only digital meeting focused on tackling the greatest analytical development challenges in the context of gene therapy drug development.

29 November - 2 December 2021

Exhibiting at Gene Therapy Analytical Development Summit

Next week we are again traveling through cyberspace and our target is the 3rd Annual Gene Therapy Analytical Development Summit. This is a conference dedicated to optimizing analytical methods to guarantee safe, high-quality, consistent, and efficacious gene therapy products.

We look forward to joining this virtual summit, the industry’s definitive and the only digital meeting focused on tackling the greatest analytical development challenges in the context of gene therapy drug development.


Visit our digital booth!

As partners of the summit, we will have our own virtual exhibit showroom - and we hope to see you there!

Here you will find more information about how we can help move Gene Therapy from a future promise to a reality.

Check-in and have a look around or take the opportunity to chat with our representatives at this event!

Our team of experts is available throughout the event and they are more than happy to answer any questions you might have. Take this opportunity to find out what answers we can provide to help out in your drug development or basic research projects.

Learn more about how we can help overcome hurdles, and move Gene Therapy from a great scientific promise to reality!

Svar Life Science contributions to this year's scientific agenda!

In addition to our Talk and Poster we are very proud and extremely honored to fulfill our scientific agenda by leading a fully attended workshop: “Stability-Indicating Assays for AAV-Based Vectors”. 

Michael G. Tovey, Ph.D, Chief Scientific Advisor of Svar Life Science France, will be leading the workshop on Mon, Nov 29.

Workshop F: 12.00pm-2.00pm (EST) 18.00-20.00 (CET)

"Stability-Indicating Assays for AAV-Based Vectors"

  • AAV-based vectors used in Gene Therapy are new and complex modalities both in terms of structure and function.
  • The mechanism of action of viral vectors is multifaceted, which requires matrixed approach for assessment of biological activity

Join this workshop to discuss:

  • Stability-indicating methods for AAV-based vectors
  • Challenges and opportunities for structure-activity relationship studies in the context of developing stability indicating assays
 

POSTER PRESENTATION

The poster will be available for download and is open for viewing and downloading during the entire summit. Our presenter has done a recording presenting the poster - please come by our booth and watch it!

"Development and characterization of a reporter gene cell line for the easy assessment of therapeutic AAV vectors - An iLite® case study"

In this poster we demonstrate the development of a technology, based upon the reporter gene assay format, that allows for assessment and quantification of the presence, activity, as well as function of a therapeutic AAV vector. Data is presented from a  proprietary developed iLite® cGMP/GC reporter gene cell line and highlights examples from the development, validation, and utilization of the genetically modified custom cell line, the subsequent assay development, and the creation of assay-ready cells.

PRESENTATION

iLite® assays for the quantification of the potency and neutralizing antibody response to recombinant AAV vectors”

TRACK: Bioassays

TIME: Tuesday, Nov 30, 1.00 pm EST (19:00 CET)

SPEAKER:
Dr.
Michael Tovey, Chief Scientific Advisor, Svar Life Science France

  • Highly sensitive assays, with an extended dynamic range, have been developed based on the iLite® reporter-gene technology for the quantification of the potency of AAV encoded transgenes regulated by photoreceptor-specific promoters without the need for helper virus or proteosome inhibitors. 

  • A highly sensitive, rapid, and serotype specific assay for the quantification of neutralizing antibodies to recombinant AAV vectors based on the iLite® technology will also be presented 

 

Won't be able to attend our contributions at the event?

If you can't join the event, you still have the opportunity to take part in our contributions.
We collect all our assets for everyone to take part in even after the events.


If you just want a tailored consultation with our team of experts, you can book a personal meeting!